NASDAQ: ILMN
Illumina, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$24.56B
52w High
$172.49
52w Low
$81.76
P/E
29.11
Volume
2.04M
Outstanding Shares
151.30M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 97.35% over the last year. Revenue grew 1.25% over the trailing twelve months. Operating margin moved from -11.76% to 21.45%. Free cash flow grew 13.81% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 14th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 21.45%. Revenue grew 1.25% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
Valuation
Stock splits
Every 1 shares became 2
Profitability & growth
Analyst consensus
25
Buy
19
Hold
6
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 30, 2026
Q3 FY26 · EPS est $1.24 · Revenue est $1.13B
View